GOSS Gossamer Bio, Inc.
Listings ·
Nasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million.
Gossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval.
Kinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate.
Gossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt.
Gossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture.
The offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants.
Gossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). Seralutinib is an investigational inhaled small molecule inhibitor of PDGFR, CSF1R and c-KIT, designed to address mechanisms that underlie PAH, including pathological remodeling. The Phase 3 PROSERA trial, a 48-week study in 390 PAH patients, reported topline results in February 2026. Seralutinib showed a placebo-adjusted improvement of 13.3 meters in six-minute walk distance at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025. In the prespecified intermediate- and high-risk subgroup of 234 patients, the placebo-adjusted improvement was 20.0 meters. The company is completing analyses of the PROSERA dataset, engaging the FDA on a regulatory path, and has paused enrollment in the SERANATA trial. It is also evaluating alternatives related to its outstanding convertible notes, and it holds an option agreement with Respira Therapeutics for RT234 in PAH and PH-ILD.
| Product or program | What it is | Stage |
|---|---|---|
| seralutinib | Inhaled PDGFR, CSF1R and c-KIT inhibitor for pulmonary arterial hypertension | Phase 3 |
| RT234 | Candidate under an option agreement with Respira Therapeutics for PAH and PH-ILD |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $48.5 million | $114.7 million |
| Research and development | $174.1 million | $138.5 million |
| Net income (loss) | -$170.4 million | -$56.5 million |
| Cash from operations | -$171.3 million | -$3.5 million |
| Cash and equivalents | $37.7 million | $46.1 million |
| Short-term investments | $99.2 million | $248.4 million |
Our latest story on this, dated Sep 28, 2026: "Gossamer Bio regains Nasdaq minimum bid price compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Gossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 21, 2026: "Gossamer Bio private placement has $150 million committed, $25.0 million at first closing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 17, 2026: "Gossamer Bio completes exchange of 2027 convertible notes into secured notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 9, 2026: "Gossamer Bio receives Nasdaq minimum bid price deficiency notice, has until October 5, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 3, 2026: "Gossamer Bio exchanges $181,052,000 of 2027 convertible notes". The story links the filing or release it is based on. Read the story.
Gossamer Bio, Inc. trades under the ticker GOSS on NASDAQ.
Gossamer Bio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4GB0.
The SEC Central Index Key (CIK) for Gossamer Bio, Inc. is 1728117. Its filings are on SEC EDGAR.
488,846,722 shares as of 2026-08-08, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Gossamer Bio, Inc. under United States.
Our directory classifies Gossamer Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Gossamer Bio, Inc. is US38341P2011.
aibio.space lists Gossamer Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,5.02,7.01,8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio